ipamorelin mastery course
Unit 9 of 11

dosing and administration

community protocols documented honestly, not validated

documented for education, not recommended

There is no FDA-approved ipamorelin dosing label. The community pattern -- 200-300 mcg subcutaneous, one to three times daily, often paired with CJC-1295 -- is consensus among gray-market users, not a clinically-validated protocol. The IV doses tested in Beck 2014 (0.03 mg/kg IV BID for postoperative ileus) do not transfer cleanly to subq community use, and human subq PK has never been formally published. This unit documents what people do, the rationale they give for it, and the math behind reconstitution. None of it is medical advice.

pulse-timing calculator

set dose, time-of-day, meal recency, and sleep window. the 24h pulse timeline updates live -- faded baseline pulses plus the predicted dose-induced pulse, scaled by Gobburu 1999 dose-linearity, somatostatin meal-suppression, and SWS-1 stacking. reconstitution math card and WADA S2.2.2 callout sit directly below.

pulse-timing calculator + reconstitution math

key terms

tap to expand.

Bbacteriostatic waterpreparation
sterile water containing 0.9% benzyl alcohol as preservative, used for reconstituting lyophilized peptides. preservative prevents bacterial growth in multi-use vials. for ipamorelin: 2 mL BAC into a 5 mg vial = 2.5 mg/mL = 2500 mcg/mL.
Iinsulin syringeequipment
a small-gauge syringe graduated in insulin units, where 100 IU = 1 mL. on a 2.5 mg/mL reconstitution, 200 mcg = 0.08 mL = 8 IU, 300 mcg = 0.12 mL = 12 IU. used for SC abdominal injection.
Ccyclingprotocol
alternating on/off periods. community lore typically describes 8-16 weeks on, 4-8 weeks off. no controlled cycling-vs-continuous comparison exists in humans -- the practice is empirical, not evidence-based.
WWADAregulatory
World Anti-Doping Agency. classifies ipamorelin under Section S2.2.2 (growth hormone secretagogues) as prohibited at all times -- both in-competition and out-of-competition -- for all athletes under WADA jurisdiction. detection is via LC-MS/MS in plasma and urine.
Ppostprandial somatostatinphysiology
somatostatin tone rises after a meal, blunting the GH pulse. this is the physiologic basis for the community practice of dosing ipamorelin at least 1 hour after a meal and at least 2 hours before/after high-fat or high-carb intake -- the goal is to dose when somatostatin tone is low.
SSC abdominalroute
subcutaneous abdominal injection -- the standard route. rotated across sites to minimize injection-site reactions. IM injection has been reported but offers no documented advantage and increases injection-site irritation.

why timing shapes the pulse -- the simple version

three reasons every protocol revolves around when, not just how much.

The first reason is somatostatin. After a meal, the hypothalamus turns up somatostatin tone, which actively suppresses GH release at the pituitary. Dosing ipamorelin right after a big meal is like flooring the accelerator with the parking brake on -- you fight against an active suppressor. Most community protocols target a 1-hour gap after meals and 2-hour gap from high-fat or high-carb intake.

The second reason is the natural sleep pulse. The largest endogenous GH pulse of the day happens during the first cycle of slow-wave sleep. A bedtime ipamorelin dose can stack on top of this peak, producing a bigger combined pulse than either alone. This is the most common timing recommendation in community protocols.

The third reason is receptor desensitization. GHS-R1a internalizes for several hours after agonist exposure. Dosing too frequently (every 1-2 hours) hits a desensitized receptor and gets a smaller pulse for the same dose. The community 4-6 hour spacing matches the receptor's recovery kinetics.

advanced: dose-linearity and the Gobburu 1999 ceiling

what Gobburu measured

single-dose IV across 4.21-140.45 nmol/kg in 48 healthy adults. PK was dose-proportional; GH response showed a sigmoidal saturation curve plateauing well before the top dose.

practical ceiling

doubling the community dose from 200 to 400 mcg does not double the GH pulse -- it adds a smaller increment because GHS-R1a occupancy is approaching saturation in the upper community range.

implication

aggressive single-dose escalation buys diminishing returns and accelerates receptor desensitization. frequency and timing tend to matter more than per-dose magnitude past ~250 mcg.

advanced: cycling rationale and the absence of controlled cycling data

the standard pattern

8-16 weeks on followed by 4-8 weeks off is the most-cited community schedule. it has no controlled-human-trial basis.

theoretical justifications

prevent receptor desensitization, allow somatotroph reserve to replenish, let IGF-1 fall back to baseline between blocks. none has been tested head-to-head against continuous dosing in a published RCT.

real limitation

the optimal pattern, if one exists, is unknown. users pick a schedule and adjust on personal observation.

advanced: practical administration and CJC-1295 stack mixing

route and technique

SC abdominal with an insulin syringe, rotated across sites. allow the alcohol swab to dry to minimize sting. bedtime preferred for SWS-1 alignment.

what to avoid

heavy meals immediately before or after dosing (postprandial somatostatin blunts the pulse). do not co-administer with glucocorticoids in the same window -- they actively suppress the GH response.

CJC-1295 no-DAC combo

both peptides are compatible in bacteriostatic water; mix in a single insulin syringe. stability follows the more-restrictive peptide -- typically 2-4 weeks refrigerated post-reconstitution.

where this has been studied

the published dosing data, what it covers, what it does not.

IV PK (Gobburu 1999)
single-dose IV in healthy adults across 4.21-140.45 nmol/kg. ~2 hour half-life, dose-proportional, GH peak at 30-40 minutes. the cleanest dose-response data available.
7-day IV (Beck 2014)
0.03 mg/kg IV twice daily for up to 7 days, postoperative ileus indication. the only multi-dose human exposure data. negative on efficacy; safety profile acceptable.
nasal absorption (animal)
Johansen 1998-1999 nasal absorption study. used as a proxy for non-IV pharmacokinetic estimates, but is animal data and the route is not the standard community route.
human subq PK
no published study of equivalent rigor. all subq community dosing estimates are extrapolated from the IV data plus animal nasal data plus receptor-desensitization kinetics. community-quoted Cmax ~30 min and half-life ~2 h are estimates, not measurements.